US · PRTA · BIOTECHNOLOGY
Prothena Corporation plc (PRTA) intrinsic value and stock valuation
$8.22as of 2026-11-21 · Mkt cap 444.48M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Prothena Corporation plc DCF and intrinsic value
InvestorsCraft values PRTA with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from PRTA’s statements →
Prothena Corporation plc Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Corvus Pharmaceuticals, Inc. (CRVS) $9.67
- Olema Pharmaceuticals, Inc. (OLMA) $7.02
- Rigel Pharmaceuticals, Inc. (RIGL) $40.09
- Verastem, Inc. (VSTM) $6.33
- 4D Molecular Therapeutics, Inc. (FDMT) $10.23
- Neumora Therapeutics, Inc. Common Stock (NMRA) $0.33
- Bicycle Therapeutics plc (BCYC) $2.90
- Gossamer Bio, Inc. (GOSS) $10.72
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $9.68M | $135.2M | $91.4M | $53.9M | $200.6M |
| Operating income | -$-184.56M | -$-154.56M | -$-191.04M | -$-131.56M | $72M |
| Net income | -$-244.09M | -$-122.31M | -$-147.03M | -$-116.95M | $67M |
| EPSd | -$-4.53M | -$-2.27M | -$-2.76M | -$-2.47M | $1.38M |
| Operating cash flow | -$-163.58M | -$-150.05M | -$-133.91M | -$-108.82M | $92.6M |
| Capital expenditure | -$-140K | -$-300K | -$-2.81M | -$-460K | -$-570K |
| Free cash flow | -$-163.72M | -$-150.35M | -$-136.72M | -$-109.28M | $92M |
| Total assets | $326.8M | $547.1M | $696.4M | $758M | $609.4M |
| Total debt | $13.9M | $10.8M | $11.8M | $6.47M | $12.3M |
| Net debt | -$-293.67M | -$-460.55M | -$-607M | -$-703.93M | -$-566.77M |
| Total equity | $280.5M | $486.9M | $561.4M | $622M | $466M |
| Cash and short-term investments | $307.5M | $471.4M | $618.8M | $710.4M | $579.1M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $9.68M | $135.2M | $91.4M | $53.9M | $200.6M |
| Cost of revenue | $3.7M | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $5.98M | $135.2M | $91.4M | $53.9M | $200.6M |
| Research and development expenses | $134.9M | $222.5M | $220.6M | $135.6M | $82.3M |
| Selling, general and administrative expenses | $59.4M | $67.2M | $61.8M | $49.9M | $46.3M |
| Other expenses | -$-3.7M | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $190.5M | $289.7M | $282.4M | $185.5M | $128.6M |
| Cost and expenses | $194.2M | $289.7M | $282.4M | $185.5M | $128.6M |
| Interest income | $14.1M | $25.8M | $31M | $6.35M | $40K |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $3.7M | $890K | $930K | $740K | $1.11M |
| Ebitda | -$-197.13M | -$-128.04M | -$-159.55M | -$-124.86M | $73M |
| Operating income | -$-184.56M | -$-154.56M | -$-191.04M | -$-131.56M | $72M |
| Total other income/expenses, net | -$-16.27M | $25.6M | $30.6M | $5.95M | -$-50K |
| Income before tax | -$-200.83M | -$-128.93M | -$-160.48M | -$-125.61M | $71.9M |
| Income tax expense | $43.3M | -$-6.62M | -$-13.45M | -$-8.66M | $4.95M |
| Net income | -$-244.09M | -$-122.31M | -$-147.03M | -$-116.95M | $67M |
| Weighted average shares outstanding | $53.8M | $53.8M | $53.2M | $47.4M | $44.2M |
| Weighted average diluted shares outstanding | $53.8M | $53.8M | $53.2M | $47.4M | $48.5M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $307.5M | $471.4M | $618.8M | $710.4M | $579.1M |
| Net receivables | $0.00 | $0.00 | $5.16M | $60K | $10K |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $315.2M | $485.4M | $639.3M | $719.1M | $584.8M |
| Property, plant and equipment, net | $10.3M | $13.8M | $16M | $8.01M | $14.1M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $860K | $860K | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $11.6M | $61.7M | $57.1M | $38.9M | $24.6M |
| Total assets | $326.8M | $547.1M | $696.4M | $758M | $609.4M |
| Accounts payable | $5.88M | $7.77M | $25.4M | $9.27M | $3.69M |
| Short-term debt | $2.89M | $2.61M | $1.11M | $6.47M | $5.94M |
| Deferred revenue | $2.66M | $8.85M | $0.00 | $11.4M | $7.66M |
| Total current liabilities | $40.8M | $48.5M | $56.9M | $50.2M | $33.5M |
| Long-term debt | $11M | $8.23M | $10.7M | $0.00 | $6.39M |
| Deferred revenue, non-current | $0.00 | $3.45M | $67.4M | $85.3M | $102.9M |
| Total non-current liabilities | $5.49M | $11.7M | $78.1M | $85.9M | $109.9M |
| Capital lease obligations | $5.49M | $10.8M | $11.8M | $6.47M | $12.3M |
| Total liabilities | $46.3M | $60.2M | $135M | $136M | $143.3M |
| Common stock | $540K | $540K | $540K | $520K | $470K |
| Retained earnings | -$-1.35B | -$-1.1B | -$-980.03M | -$-833M | -$-716.05M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total equity | $280.5M | $486.9M | $561.4M | $622M | $466M |
| Total investments | $860K | $860K | $0.00 | $0.00 | $0.00 |
| Total debt | $13.9M | $10.8M | $11.8M | $6.47M | $12.3M |
| Net debt | -$-293.67M | -$-460.55M | -$-607M | -$-703.93M | -$-566.77M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-244.09M | -$-122.31M | -$-147.03M | -$-116.95M | $67M |
| Depreciation and amortization | $900K | $890K | $930K | $740K | $1.11M |
| Stock-based compensation | $37.6M | $46M | $40.9M | $31.3M | $24.7M |
| Change in working capital | -$-4.17M | -$-67.94M | -$-20.53M | -$-18.8M | -$-10.4M |
| Accounts receivable | $0.00 | $5.16M | -$-5.16M | $0.00 | $10K |
| Inventory | $0.00 | $0.00 | -$-8.9M | $0.00 | $0.00 |
| Accounts payable | -$-15.78M | -$-18.3M | $22.9M | $11.9M | -$-490K |
| Net cash provided by operating activities | -$-163.58M | -$-150.05M | -$-133.91M | -$-108.82M | $92.6M |
| Investments in property, plant and equipment | -$-140K | -$-300K | -$-2.81M | -$-460K | -$-570K |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-140K | -$-300K | -$-2.77M | -$-460K | -$-570K |
| Common stock issued | -$-140K | $0.00 | $23.6M | $223.6M | $174.8M |
| Common stock repurchased | $0.00 | -$-350K | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-140K | $1.55M | $45.1M | $241.5M | $190.3M |
| Net change in cash | -$-163.86M | -$-148.79M | -$-91.58M | $132.2M | $282.4M |
| Cash at end of period | $308.4M | $472.3M | $621M | $712.6M | $580.5M |
| Operating cash flow | -$-163.58M | -$-150.05M | -$-133.91M | -$-108.82M | $92.6M |
| Capital expenditure | -$-140K | -$-300K | -$-2.81M | -$-460K | -$-570K |
| Free cash flow | -$-163.72M | -$-150.35M | -$-136.72M | -$-109.28M | $92M |
Line items
Line items
Line items
About Prothena Corporation plc
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
- CEO
- Gene G. Kinney
- Employees
- 67
- Beta
- -0.35
Explore
Frequently asked questions
What is the intrinsic value of Prothena Corporation plc (PRTA)?
Prothena Corporation plc (PRTA) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is PRTA undervalued?
PRTA trades at a price of $8.22 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.